United States — Food and Drug Administration & Pomerantz LLP

United States — Food and Drug Administration: The United States — Food and Drug Administration issued Complete Response Letters and placed a clinical hold on Atara Biotherapeutics' Investigational New Drug applications, citing manufacturing issues and deficiencies in the ALLELE study, which directly impacted the company's stock price and led to the class action.

Pomerantz LLP: Pomerantz LLP filed the class action lawsuit against Atara Biotherapeutics on behalf of investors, seeking to recover damages for alleged violations of federal securities laws.